Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- NBI and Pfizer to Initiate e-Detailing for Spiriva
March 31, 2008
- GSK Promotes Adoair Anticipating Lifting of 2-Week Limitation on Prescriptions
March 31, 2008
- Kissei Has Candidate for Next Global Strategic Product at PI: President Kanzawa
March 31, 2008
- MEDICAL DEVICE NEWS IN BRIEF
March 31, 2008
- Astellas to Enhance Global Management System
March 31, 2008
- R&D NEWS IN BRIEF
March 31, 2008
- Takeda Announces Restructuring of US Operations
March 31, 2008
- Over 50% of Companies to Hire More New Graduates
March 24, 2008
- Japanese Companies Start Voluntary Recall of Heparin Products
March 24, 2008
- Opinion Statement on Closing Vaccine Gap Issued by EFPIA Japan
March 24, 2008
- Korosho Completes Hearings of 16 Leading Manufacturers
March 24, 2008
- Need to Permanently Post Experts Stressed by Group Members
March 24, 2008
- Pfizer to Start 28 PIII Studies in Cancer, Diabetes, Pain
March 24, 2008
- SELF-MEDICATION NEWS IN BRIEF
March 24, 2008
- Novo Nordisk to Apply for Liraglutide in 2008: Mr Eilersen
March 24, 2008
- Lilly Terminates Development of Inhaled Insulin
March 24, 2008
- MEDICAL DEVICE NEWS IN BRIEF
March 24, 2008
- Zeria to Codevelop Remedy for FD with Astellas
March 24, 2008
- Herceptin Postoperative Adjuvant Chemotherapy Judged to Be Cost Effective
March 24, 2008
- Competitors' Exodus Gives Better Chance to NBI: Dr Nishikawa
March 24, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…